Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

“This new class of immunotherapy drug traps white blood cells in the lymph nodes to prevent their escape into the gut where they cause inflammation,” said William J. Sandborn, MD … Read the Full Story from the UC San Diego Newsroom

Dr. William Sandborn

Dr. William Sandborn

William Sandborn, MD, is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC San Diego.

Read the article abstract in the New England Journal of Medicine.

%d bloggers like this: